The menopause health gap is a pressing issue that affects millions of women worldwide, yet it remains largely hidden from public discourse. Vaginal dryness, a common symptom during and after menopause, is experienced by over half of women, yet an astonishing 70% of them never discuss it with their healthcare provider. This silence perpetuates an injustice and presents an opportunity for innovation in women's health.
As an entrepreneur, I've always been drawn to solving problems that matter. When I delved into women's health, I noticed a stark disparity in innovation. While there's a wealth of research and products focused on fertility and pregnancy, the same cannot be said for perimenopause and its associated symptoms. This realization sparked my journey with Biolae, a company dedicated to addressing this gap.
Together with my co-founder, Maryalice Rosa, we identified a critical need for clinically validated, non-hormonal solutions for perimenopause. The science behind many existing products was lacking, leaving healthcare professionals with limited options to recommend to their patients. We set out to change this by prioritizing clinical validity in our product development.
At Biolae, we hold ourselves to the highest standards of evidence-based formulation. Our ingredients are backed by gold-standard clinical trials, dosed at therapeutic levels, and every batch undergoes independent testing for purity and potency. This commitment to scientific rigor sets us apart and ensures that our products are both effective and safe.
One of our most significant milestones is the upcoming launch of Australia's first TGA-listed hyaluronic acid pessary. This product, developed over three years, represents a major step forward in women's health. Launching a first-to-market medical device in a personal and intimate category comes with immense responsibility, and I approach it with a deep sense of purpose.
Vaginal dryness is not solely a menopause symptom; it can also occur postpartum, during stressful periods, or as a side effect of certain medications. By pulling it out from under the menopause umbrella, we aim to destigmatize the conversation and bring vaginal dryness into the open. This shift is crucial to addressing the education gap and empowering women to take charge of their health.
The cultural conversation around menopause has evolved, but vaginal dryness remains a taboo topic. This silence contributes to the real impact we aim to address. Building in underserved spaces is exhilarating, as it requires breaking new ground without a clear playbook. Launching a first-to-market medical device in consumer health is a rare opportunity, and we embrace the challenge it presents.
Our marketing approach, Not-So-Dry July, is designed to educate women about vaginal dryness while making the conversation less intimidating. Humor, when used thoughtfully, can break down stigma and encourage open dialogue. It's a delicate balance, but one that I believe is essential to fostering a supportive environment.
Looking ahead, our next big frontier is the pharmacy. By entering this space, we aim to reshape how retailers perceive menopause and the role of these products in women's lives. The menopause shelf's placement in stores reflects the historical undervaluing of this category, and we're determined to change that.
The journey with Biolae has been anything but linear. We've faced setbacks, pivoted, and navigated moments of uncertainty, but it's all part of the startup experience. As we continue to innovate in women's health, I'm excited about the future. There are still countless unmet needs waiting to be addressed, and I'm eager to be at the forefront of this transformative journey.
